Ebola Virus Gene Replikins Found Conserved and Shared in All Ebola Strains Back to 1976 - NEWS10 ABC: Albany, New York News, Weather, Sports

Ebola Virus Gene Replikins Found Conserved and Shared in All Ebola Strains Back to 1976

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Replikins

Latest Analysis Provides Basis for a Synthetic Ebola Blocker-Vaccine Candidate, Now Available for Testing

LONDON, Aug. 26, 2014 /PRNewswire/ -- An analysis by Replikins, Ltd. of Pubmed data of the gene structures of all Ebola strains has revealed extensive conservation and sharing of specific Replikin structures back to 1976.  This conservation and sharing of specific Replikin gene structures has paved the way for the development of a synthetic Ebola Blocker-Vaccine candidate, as it did for the H5N1 influenza vaccine and the Taura Syndrome Shrimp vaccine, both of which have been found to be effective (1,2).

This Ebola vaccine candidate is synthesized in five days and is available freeze-dried to governments and other institutions for testing and use according to the country's regulatory bodies.

For further information:

646-320-5910

Email

References:

1. Jackwood et al. Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53:613-617, 2009.

2. Bogoch S and Bogoch ES. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1?

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

341 Northern Blvd., Albany, NY 12204

Telephone: 518.436.4822
Fax: 518.426.4792
Email: news@news10.com

Can’t find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Young Broadcasting of Albany, Inc. A Media General Company.